NASDAQ$TGTX
TG Therapeutics Inc. · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
TG Therapeutics reported fourth quarter and year-end 2021 financial results and provided a business update for 2022.
TG Therapeutics reported product revenue of $2.3 million for the fourth quarter of 2021. The company's R&D expenses were $62.6 million and SG&A expenses were $32.4 million. Net loss for the quarter was $93.3 million. The company ended the year with over $350 million in cash, cash equivalents and investment securities.
- U.S. FDA accepted the BLA for ublituximab, with a PDUFA goal date of September 28, 2022.
- FDA accepted a BLA for ublituximab and a supplemental New Drug Application (sNDA) for UKONIQ, applications were based on results from the UNITY-CLL Phase 3 trial.
- Generated $6.5 million in total net UKONIQ revenue from launch through the end of Q4 2021.
- Ended the year with more than $350 million in cash, cash equivalents and investment securities.
Headline financials
Revenue & EPS history
TG Therapeutics · Revenue · Quarterly
$2.32M
Forward guidance
TG Therapeutics is focused on obtaining a favorable outcome at the upcoming ODAC meeting, obtaining FDA approval of U2 in CLL and SLL, obtaining FDA approval of ublituximab in RMS, and continuing to advance our early pipeline candidates.
Tailwinds
- Obtain a favorable outcome at the upcoming ODAC meeting.
- Obtain FDA approval of U2 in CLL and SLL.
- Obtain FDA approval of ublituximab in RMS.
- Continue to advance our early pipeline candidates including TG-1501 (cosibelimab), our PDL1 inhibitor.
- Continue to advance TG-1701, our BTK inhibitor and TG-1801 our CD47/CD19 bispecific antibody.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+2.7%
Avg return
Earnings day
+5.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
49%
27 / 55 earnings
Positive
+81.0%
Q3 2022
Best reaction
-49.0%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +16.3% | +19.4% | +11.1% | |
| Q4 2025 | +4.3% | -2.6% | +7.0% | |
| Q3 2025 | -1.0% | -7.3% | -9.1% | |
| Q1 2025 | -13.4% | -22.6% | -14.7% | |
| Q4 2024 | +14.4% | +27.8% | +32.3% | |
| Q3 2024 | -3.9% | +7.1% | +25.9% | |
| Q2 2024 | +16.2% | +15.7% | +24.7% | |
| Q1 2024 | +20.2% | +20.9% | +19.3% | |
| Q4 2023 | +23.8% | +28.5% | +9.3% | |
| Q3 2023 | +34.7% | +32.6% | +78.9% | |
| Q2 2023 | -49.0% | -48.2% | -49.4% | |
| Q1 2023 | +25.5% | +38.1% | +7.2% | |
| Q4 2022 | -3.8% | +7.8% | -8.2% | |
| Q3 2022 | +81.0% | +70.7% | +45.7% | |
| Q2 2022 | +19.4% | +33.4% | +9.1% | |
| Q1 2022 | -10.9% | +1.4% | -24.5% | |
| Q4 2021 | +4.7% | -11.1% | -3.6% | |
| Q3 2021 | +7.9% | +5.3% | -52.5% | |
| Q2 2021 | -27.2% | -32.8% | -15.8% | |
| Q1 2021 | -6.7% | -14.8% | -7.2% | |
| Q4 2020 | -5.0% | -3.8% | +8.8% | |
| Q3 2020 | -0.2% | +4.4% | +5.0% | |
| Q2 2020 | -12.0% | +2.6% | +22.3% | |
| Q1 2020 | +5.9% | +2.6% | -6.0% | |
| Q4 2019 | -4.1% | -13.6% | -32.6% | |
| Q3 2019 | +1.4% | +2.7% | +20.6% | |
| Q2 2019 | +3.3% | +0.1% | -8.4% | |
| Q1 2019 | -15.5% | -13.4% | -8.0% | |
| Q4 2018 | +0.4% | -8.1% | +18.2% | |
| Q3 2018 | +2.5% | -1.1% | -4.4% | |
| Q2 2018 | -3.4% | -0.4% | +0.0% | |
| Q1 2018 | -3.7% | -2.6% | +3.7% | |
| Q4 2017 | +8.5% | +10.2% | -15.1% | |
| Q3 2017 | +9.9% | +9.3% | +12.6% | |
| Q2 2017 | +1.0% | +16.0% | +22.0% | |
| Q1 2017 | +2.5% | +11.3% | +36.5% | |
| Q4 2016 | +3.4% | +22.5% | -10.6% | |
| Q3 2016 | +1.0% | +6.7% | -1.9% | |
| Q2 2016 | -7.6% | -0.2% | +13.3% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -6.8% | — | — | |
| Q3 2015 | +8.4% | — | — | |
| Q2 2015 | -2.2% | — | — | |
| Q1 2015 | -6.0% | — | — | |
| Q3 2014 | +14.6% | — | — | |
| Q1 2012 | -3.7% | — | — | |
| Q2 2012 | -14.3% | — | — | |
| Q4 2011 | -23.0% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +36.4% | — | — | |
| Q4 2010 | +7.7% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro